David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Opening Session Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Feb

Today In Oncology

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Opening Session Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Deep Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC

Novel HER2-Targeted Bispecific Benefits Outcomes in Gastroesophageal Cancer

Randomized Trial Shows AI-Supported Mammography Improves Sensitivity and Lowers Interval Cancer Rate

Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma

Head and Neck Cancer How Does Genetic Ancestry Impact Tumor Genomics